Developing Therapeutics That Teach the Body to Heal Itself
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about potential milestones and significant inflection points ...
Featured Stories AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial...
Newsletter Vol. 7 In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Vid...
NEWSLETTER VOL. 6 AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on socia...
End of year wrap-up Q4, 2017 Newsletter AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the p...
AGT IN THE SPOTLIGHT American Gene Technologies International CEO, Jeff Galvin, is increasingly in demand for his thought leadership in addition to his vision for AGT. Jeff was invited to deliver the closing pre...
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
